Biosimilar Interchangeability Switching Studies May Use Foreign Comparators, US FDA Says

But scientific bridging required for non-US reference products might be more extensive than in other contexts, agency cautions; easing of the US comparator-only recommendation is one of several changes from the 2017 draft guidance that could make pursuing an interchangeability designation easier.

bridge-completion
Building a bridge between foreign and US reference products might be more difficult for showing interchangeability than biosimilarity. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics